J0650
J0650 – Inj, levothyroxine nos 10mcg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 18 NDCs crosswalked per 10 MCG $5.096/unit ASP+6%
📋 J0650 summary
J0650 is a HCPCS Level II J-code used to bill levothyroxine nos 10mcg, billed per 10 MCG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0650: Levothyroxine Sodium(J0650)
Code J0650
Billing unit 10 MCG Payment limit $5.096/unit NDC-Crosswalk 18
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0650
DescriptorInj, levothyroxine nos 10mcg
Billing unit10 MCG
Payment limit / unit$5.096
Est. ASP / unit$4.808 est.
Mapped NDCs18
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$5.096
Est. ASP / unit
$4.808 est.
Est. after 2% sequester
$4.994
HCPCS dosage
10 MCG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0650 = 10 mcg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0650 WITH EST. MEDICARE PAY
18 NDCs map to J0650. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($5.096/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 25021-0468-10 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 1 VIAL in 1 CARTON (25021-468-10) / 5 mL... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS + PDAC |
| 25021-0469-10 | Levothyroxine Sodium 200 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 1 VIAL in 1 CARTON (25021-469-10) / 5 mL... | 200 ug/5mL | 20 | $101.92 | — | ● Active | CMS + PDAC |
| 25021-0470-10 | Levothyroxine Sodium 500 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 1 VIAL in 1 CARTON (25021-470-10) / 5 mL... | 500 ug/5mL | 50 | $254.80 | — | ● Active | CMS + PDAC |
| 42023-0201-01 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ENDO | 1 VIAL, SINGLE-DOSE in 1 CARTON (42023-201... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS + PDAC |
| 42023-0202-01 | Levothyroxine Sodium 200 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ENDO | 1 VIAL, SINGLE-DOSE in 1 CARTON (42023-202... | 200 ug/5mL | 20 | $101.92 | — | ● Active | CMS + PDAC |
| 42023-0203-01 | Levothyroxine Sodium 500 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ENDO | 1 VIAL, SINGLE-DOSE in 1 CARTON (42023-203... | 500 ug/5mL | 50 | $254.80 | — | ● Active | CMS + PDAC |
| 63323-0647-10 | Levothyroxine Sodium 200 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-647... | 200 ug/5mL | 20 | $101.92 | — | ● Active | CMS ASP |
| 63323-0648-10 | Levothyroxine Sodium 500 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-648... | 500 ug/5mL | 50 | $254.80 | — | ● Active | CMS ASP |
| 63323-0649-07 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-649... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS ASP |
| 63323-0649-16 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-649... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS + PDAC |
| 63323-0649-94 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-649... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS ASP |
| 70710-1833-01 | LEVOTHYROXINE SODIUM 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Zydus | 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-183... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS + PDAC |
| 70710-1834-01 | LEVOTHYROXINE SODIUM 200 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Zydus | 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-183... | 200 ug/5mL | 20 | $101.92 | — | ● Active | CMS + PDAC |
| 70710-1835-01 | LEVOTHYROXINE SODIUM 500 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Zydus | 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-183... | 500 ug/5mL | 50 | $254.80 | — | ● Active | CMS + PDAC |
| 70860-0451-10 | Levothyroxine Sodium | Athenex | — | — | 10 | $50.96 | — | — | CMS + PDAC |
| 70860-0452-10 | Levothyroxine Sodium | Athenex | — | — | 20 | $101.92 | — | — | CMS + PDAC |
| 70860-0453-10 | Levothyroxine Sodium | Athenex | — | — | 50 | $254.80 | — | — | CMS + PDAC |
| 72266-0261-01 | Levothyroxine Sodium 100 ug/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fosun | 1 VIAL, SINGLE-DOSE in 1 CARTON (72266-261... | 100 ug/5mL | 10 | $50.96 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$3.4K
Claims
30
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$113.95
Trend by period
Where J0650 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #723 of 824
#718
ERAXIS J0348
$3.8K
#719
ACETAMINOPHEN(J0131) J0131
$3.7K
#720
VASOPRESSIN-0.9% NAC... J2601
$3.7K
#721
DDAVP* J2597
$3.6K
#722
DEMEROL* J2175
$3.4K
#723
LEVOTHYROXINE SODIUM... J0650
$3.4K
#724
MESNA* J9209
$3.4K
#725
CYSTO-CONRAY II* Q9958
$3.3K
#726
ENGERIX-B PEDIATRIC-... 90744
$3.2K
#727
TESTOSTERONE ENANTHA... J3121
$3.1K
#728
DOPAMINE HCL IN 5% D... J1265
$3.1K
Total claims — #741 of 824
#736
ALPHANATE J7186
32
#737
ELZONRIS J9269
32
#738
TEPADINA(J9342)* J9342
32
#739
ERZOFRI J2428
31
#740
TIGAN J3250
31
#741
LEVOTHYROXINE SODIUM... J0650
30
#742
TEMODAR J9328
30
#743
CYGNUS, PER SQ CM** Q4170
30
#744
BRIXADI(J0577) J0577
29
#745
HYPERRHO* J2790
29
#746
ZIEXTENZO Q5120
29
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $3.4K | — | 30 | — | $113.95 |
| 2025 (Q1-Q4) | $22.9K | — | 127 | — | $179.92 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$23.1K
Medicare paid
$18K
Submitted services
6,913
Denial rate
37.9%
Allowed / service
$5.40
Submitted charges
$323.5K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J0650 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J0650
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
18 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0650 billing FAQ
What is HCPCS code J0650?
J0650 is a HCPCS Level II J-code used to bill Inj, levothyroxine nos 10mcg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0650?
One unit of J0650 represents 10 MCG. Report the number of units equal to the dose administered divided by 10 MCG.
How many units of J0650 should I bill?
Divide the dose administered by the code's unit size (10 MCG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0650?
The Medicare Part B payment limit is $5.096 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $4.994 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0650?
18 NDCs currently map to J0650 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0650 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.